Aclipse Therapeutics

Headquarters

King Of Prussia, PA

Aclipse Therapeutics develops novel and highly differentiated therapeutics to treat life-threatening and severe diseases, leveraging genomic, proteomic, and biomarker data to develop disease-modifying drug candidates. The company focuses on molecular pathways regulating inflammation, cellular stress, and protein misfolding, with a pipeline including M107 for gastroparesis and M102 for ALS.

• Amyndas PharmaceuticalsAmyndas Pharmaceuticals is a pharmaceutical company developing potent complement therapeutics for inflammatory diseases and disorders based on its patented technology for modulating the complement system. The company focuses on next-generation Compstatins, including AMY-101 and AMY-201, for conditions such as age-related macular degeneration, periodontal disease, and complement-mediated disorders.PHILADELPHIA, PA
• ZyVersa Therapeutics, IncZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for inflammatory and renal diseases. It leverages two proprietary platforms: an inflammasome ASC inhibitor (IC 100) for inflammatory conditions and a cholesterol efflux mediator (VAR 200) for kidney diseases.WEST CONSHOHOCKEN, PA
• Neuropathix, IncNeuropathix, Inc. is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics targeting inflammation to treat patients with significant unmet medical needs. The company's lead candidate is KLS-13019, a patented, non-opioid cannabinoid derivative for neuropathic pain.DOYLESTOWN, PA
• AT
  Alteris Therapeutics IncAlteris Therapeutics Inc. operates in the pharmaceutical manufacturing industry.PHILADELPHIA, PA